DNMT1 and plasma cell myeloma: Considering that a moiety of the tinostamustine molecule has HDAC inhibitor activity [30], our data are consistent with previous observations that epigenetic drugs such as DNMT or HDAC inhibitors increase CD38 expression in myeloma cells [18,19,20].